Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The transaction is expected to close in the first quarter of 2022
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
Biogen paid Ionis a US $ 60 million one-time upfront payment
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The product is expected to be available in a week’s time
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Subscribe To Our Newsletter & Stay Updated
